Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Works (26)

Langerhans cells: Central players in the pathophysiology of atopic dermatitis

Journal of the European Academy of Dermatology and Venereology
2025-02 | Journal article
DOI: 10.1111/jdv.20291
Contributors: Yi Pan; Mathias Hochgerner; Małgorzata Anna Cichoń; Theresa Benezeder; Thomas Bieber; Peter Wolf
Source: check_circle
Crossref

The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification

Annals of Allergy, Asthma & Immunology
2025-02 | Journal article
DOI: 10.1016/j.anai.2024.09.022
Contributors: Thomas Bieber
Source: check_circle
Crossref

Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy

Circulation: Heart Failure
2025-02-18 | Journal article
DOI: 10.1161/CIRCHEARTFAILURE.124.011796
Contributors: Stéphanie Kristina Schwarting; Thomas Bieber; Daniel R. Davies; Fabian aus dem Siepen; Julian Schwarting; Ulrich Grabmaier; Steffen Massberg; Mathew S. Maurer; Stefan Kääb
Source: check_circle
Crossref

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

Drugs
2024-11 | Journal article
DOI: 10.1007/s40265-024-02095-4
Contributors: José Miguel Alvarenga; Thomas Bieber; Tiago Torres
Source: check_circle
Crossref

Will deciphering the epidermal ‘ménage à trois’ lead to predictive biomarkers for childhood atopic dermatitis?

Journal of the European Academy of Dermatology and Venereology
2024-09 | Journal article
DOI: 10.1111/jdv.20180
Contributors: Thomas Bieber
Source: check_circle
Crossref

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Allergy
2024-06 | Journal article
DOI: 10.1111/all.16009
Contributors: Svenja Müller; Laura Maintz; Thomas Bieber
Source: check_circle
Crossref

Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the “Flip‐Flop” phenomenon)

Allergy
2024-01 | Journal article
DOI: 10.1111/all.15921
Contributors: Svenja Müller; Thomas Welchowski; Matthias Schmid; Laura Maintz; Nadine Herrmann; Dagmar Wilsmann‐Theis; Thorben Royeck; Regina Havenith; Thomas Bieber
Source: check_circle
Crossref

Evidence for a restoration of TLR2 response in epidermal dendritic cells in atopic dermatitis by topical anti‐inflammatory therapy

Allergy
2024-01 | Journal article
DOI: 10.1111/all.15899
Contributors: Marie‐Sophie Philipp; Tim J. Nümm; Yuxuan Deng; Kazumasa Iwamoto; Nadine Herrmann; Thomas Bieber
Source: check_circle
Crossref

Immunoglobulin E autoantibodies in atopic dermatitis associate with Type‐2 comorbidities and the atopic march

Allergy
2023-12 | Journal article
DOI: 10.1111/all.15822
Contributors: Inge Kortekaas Krohn; Fariza Mishaal Saiema Badloe; Nadine Herrmann; Laura Maintz; Shauni De Vriese; Johannes Ring; Thomas Bieber; Jan Gutermuth
Source: check_circle
Crossref

Author Correction: Disease modification in inflammatory skin disorders: opportunities and challenges

Nature Reviews Drug Discovery
2023-11 | Journal article
DOI: 10.1038/s41573-023-00790-7
Contributors: Thomas Bieber
Source: check_circle
Crossref

Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition

Allergy
2023-11 | Journal article
DOI: 10.1111/all.15811
Contributors: Eric L. Simpson; Emma Guttman‐Yassky; Lawrence F. Eichenfield; Mark Boguniewicz; Thomas Bieber; Shannon Schneider; Adriana Guana; Jonathan I. Silverberg
Source: check_circle
Crossref

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

Nature Reviews Drug Discovery
2023-09 | Journal article
DOI: 10.1038/s41573-023-00750-1
Contributors: Pavel Kolkhir; Cezmi A. Akdis; Mübeccel Akdis; Claus Bachert; Thomas Bieber; Giorgio Walter Canonica; Emma Guttman-Yassky; Martin Metz; Joaquim Mullol; Oscar Palomares et al.
Source: check_circle
Crossref

Disease modification in inflammatory skin disorders: opportunities and challenges

Nature Reviews Drug Discovery
2023-08 | Journal article
DOI: 10.1038/s41573-023-00735-0
Contributors: Thomas Bieber
Source: check_circle
Crossref

Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis

Clinical and Experimental Dermatology
2023-07-21 | Journal article
DOI: 10.1093/ced/llad129
Contributors: Thomas Bieber; Jacob P Thyssen; Alan D Irvine; Yuichiro Tsunemi; Yun-Fei Chen; Luna Sun; Andrea Schloebe; Elisabeth Riedl; Michael J Cork
Source: check_circle
Crossref

Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status

JID Innovations
2022-03 | Journal article
DOI: 10.1016/j.xjidi.2021.100092
Contributors: Takashi Sakai; Nadine Herrmann; Laura Maintz; Tim Joachim Nümm; Thomas Welchowski; Ralf A. Claus; Markus H. Gräler; Thomas Bieber
Source: check_circle
Crossref

Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients—Focus on Clinical and Histopathological Variation

Dermatopathology
2022-03-18 | Journal article
DOI: 10.3390/dermatopathology9010010
Contributors: Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Source: check_circle
Crossref

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

Nature Reviews Drug Discovery
2022-01 | Journal article
DOI: 10.1038/s41573-021-00266-6
Contributors: Thomas Bieber
Source: check_circle
Crossref

Serum receptor activator of nuclear factor kappa‐Β ligand/osteoprotegerin ratio correlates with severity and suggests fracture's risk in older women with atopic dermatitis

Allergy
2021-10 | Journal article
DOI: 10.1111/all.14971
Contributors: Takashi Sakai; Nadine Herrmann; Laura Maintz; Tim Joachim Nümm; Thomas Welchowski; Thomas Bieber
Source: check_circle
Crossref

Serum sphingosine‐1‐phosphate is elevated in atopic dermatitis and associated with severity

Allergy
2021-08 | Journal article
DOI: 10.1111/all.14826
Contributors: Takashi Sakai; Nadine Herrmann; Laura Maintz; Tim Joachim Nümm; Thomas Welchowski; Ralf A. Claus; Markus H. Gräler; Thomas Bieber
Source: check_circle
Crossref

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

British Journal of Dermatology
2021-03-22 | Journal article
DOI: 10.1111/bjd.19573
Contributors: J.I. Silverberg; D. Toth; T. Bieber; A.F. Alexis; B.E. Elewski; A.E. Pink; D. Hijnen; T.N. Jensen; B. Bang; C.K. Olsen et al.
Source: check_circle
Crossref

Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial

American Journal of Clinical Dermatology
2021-03-03 | Journal article
DOI: 10.1007/s40257-020-00583-3
Contributors: Elaine C. Siegfried; Thomas Bieber; Eric L. Simpson; Amy S. Paller; Lisa A. Beck; Mark Boguniewicz; Lynda C. Schneider; Faisal A. Khokhar; Zhen Chen; Randy Prescilla et al.
Source: check_circle
Crossref

Unraveling the complexity of atopic dermatitis: The CK‐CARE approach toward precision medicine

Allergy
2020-11 | Journal article
DOI: 10.1111/all.14194
Contributors: Thomas Bieber; Claudia Traidl‐Hoffmann; Georg Schäppi; Roger Lauener; Cezmi Akdis; Peter Schmid‐Grendlmeier
Source: check_circle
Crossref

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

Allergy
2020-01 | Journal article
DOI: 10.1111/all.13954
Contributors: Thomas Bieber
Source: check_circle
Crossref

Targeting T2 Inflammation by Dupilumab Impacts on the Microbiomic “Ménage à Trois” of Atopic Dermatitis

Journal of Investigative Dermatology
2020-01 | Journal article
DOI: 10.1016/j.jid.2019.07.680
Contributors: Thomas Bieber
Source: check_circle
Crossref

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

American Journal of Clinical Dermatology
2019-06-07 | Journal article
DOI: 10.1007/s40257-019-00445-7
Contributors: Lawrence F. Eichenfield; Thomas Bieber; Lisa A. Beck; Eric L. Simpson; Diamant Thaçi; Marjolein de Bruin-Weller; Mette Deleuran; Jonathan I. Silverberg; Carlos Ferrandiz; Regina Fölster-Holst et al.
Source: check_circle
Crossref

Allergy—Committed to progress in allergy and immunology

Allergy
2018-03 | Journal article
DOI: 10.1111/all.13412
Contributors: H.‐U. Simon; T. Bieber
Source: check_circle
Crossref

Peer review (5 reviews for 4 publications/grants)

Review activity for Drugs (1)
Review activity for Nature communications (1)
Review activity for Nature medicine. (1)
Review activity for The journal of allergy and clinical immunology (2)
How many people are using ORCID?